A Phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma
- 1 December 1996
- journal article
- other
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (13), 2366-2368
- https://doi.org/10.1016/s0959-8049(96)00280-8
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Resistence to cytotoxic therapy: A speculative overviewAnnals of Oncology, 1995
- Treatment of hepatocellular carcinoma: too many options?Journal of Clinical Oncology, 1994
- MDR1 Gene Expression: Its Effect on Drug Resistance to Doxorubicin in Human Hepatocellular Carcinoma Cell LinesJNCI Journal of the National Cancer Institute, 1994
- High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With VinblastineJNCI Journal of the National Cancer Institute, 1992
- Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinomaDigestive Diseases and Sciences, 1992
- Overexpression of the MDR1 Gene and P-Glycoprotein in Human Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 1992